Compare BRBS & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BRBS | TECX |
|---|---|---|
| Founded | 1893 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.3M | 366.8M |
| IPO Year | N/A | 2018 |
| Metric | BRBS | TECX |
|---|---|---|
| Price | $4.30 | $19.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $80.40 |
| AVG Volume (30 Days) | 148.3K | ★ 225.8K |
| Earning Date | 01-29-2026 | 03-19-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $95,697,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.92 | $13.70 |
| 52 Week High | $4.79 | $61.07 |
| Indicator | BRBS | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 50.53 |
| Support Level | $4.25 | $18.78 |
| Resistance Level | $4.37 | $20.66 |
| Average True Range (ATR) | 0.10 | 1.26 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 4.35 | 65.50 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.